06:10 EDT Travere falls 14% to $18.10 after FDA does not grant priority review
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- Travere Therapeutics selloff should be bought, says Citi
- Buy Rating Reaffirmed for Travere Therapeutics Amid FDA Review and Market Overreaction
- Closing Bell Movers: Applied Materials down over 5% after Q2 results
- Travere Therapeutics’ FDA Acceptance for FILSPARI Application
- Travere Therapeutics announces FDA acceptance of sNDA for Filspari
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue